PL2115472T3 - Biomarkery nowotworowe - Google Patents

Biomarkery nowotworowe

Info

Publication number
PL2115472T3
PL2115472T3 PL07848631T PL07848631T PL2115472T3 PL 2115472 T3 PL2115472 T3 PL 2115472T3 PL 07848631 T PL07848631 T PL 07848631T PL 07848631 T PL07848631 T PL 07848631T PL 2115472 T3 PL2115472 T3 PL 2115472T3
Authority
PL
Poland
Prior art keywords
cancer biomarkers
biomarkers
cancer
Prior art date
Application number
PL07848631T
Other languages
English (en)
Inventor
Hardev Pandha
Richard George Leonard Morgan
Original Assignee
The Univ Of Surrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Of Surrey filed Critical The Univ Of Surrey
Publication of PL2115472T3 publication Critical patent/PL2115472T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
PL07848631T 2006-12-19 2007-12-19 Biomarkery nowotworowe PL2115472T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0625321.5A GB0625321D0 (en) 2006-12-19 2006-12-19 Cancer biomarker
GBGB0719792.4A GB0719792D0 (en) 2006-12-19 2007-10-10 Cancer biomarkers
EP07848631.3A EP2115472B1 (en) 2006-12-19 2007-12-19 Cancer biomarkers
PCT/GB2007/004902 WO2008075056A1 (en) 2006-12-19 2007-12-19 Cancer biomarkers

Publications (1)

Publication Number Publication Date
PL2115472T3 true PL2115472T3 (pl) 2014-05-30

Family

ID=39265269

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07848631T PL2115472T3 (pl) 2006-12-19 2007-12-19 Biomarkery nowotworowe

Country Status (19)

Country Link
US (1) US8460882B2 (pl)
EP (1) EP2115472B1 (pl)
JP (1) JP5683108B2 (pl)
CN (1) CN101675341B (pl)
AU (1) AU2007335999B2 (pl)
BR (1) BRPI0720371B8 (pl)
CA (1) CA2671939C (pl)
CY (1) CY1115178T1 (pl)
DK (1) DK2115472T3 (pl)
ES (1) ES2445185T3 (pl)
GB (2) GB0625321D0 (pl)
IL (1) IL199241A (pl)
MX (1) MX2009006378A (pl)
NZ (1) NZ577548A (pl)
PL (1) PL2115472T3 (pl)
PT (1) PT2115472E (pl)
RU (1) RU2460075C2 (pl)
SI (1) SI2115472T1 (pl)
WO (1) WO2008075056A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
DE102006047617B4 (de) 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
DE102008017216B4 (de) 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
GB0823445D0 (en) * 2008-12-23 2009-01-28 Univ Surrey Biomarker
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
GB0912175D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
EP2454597A1 (en) * 2009-07-13 2012-05-23 The University of Surrey Therapeutic peptides, polypeptides ans nucleic acid sequences
GB0912190D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
GB0921329D0 (en) * 2009-12-04 2010-01-20 Univ Surrey Biomarker
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
US20140106363A1 (en) * 2011-05-12 2014-04-17 Noviogendix Research B.V. Molecular markers in prostate cancer
CA2835728A1 (en) * 2011-05-12 2012-11-15 Noviogendix Research B.V. Molecular markers in prostate cancer
CN103797120B (zh) * 2011-09-16 2017-04-12 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
WO2013085483A1 (en) * 2011-12-05 2013-06-13 Phigenix, Inc. Targeting en2, pax2, and/or defb1 for treatment of prostate conditions
US9110030B2 (en) 2012-06-29 2015-08-18 Daniel A. Kerschensteiner Colorimetric gelatinase assay
US10613087B2 (en) * 2012-08-10 2020-04-07 Analiza, Inc. Methods and devices for analyzing species to determine diseases
CN105324670B (zh) * 2013-05-09 2018-08-03 宝洁公司 用于评估健康状况的方法和系统
WO2016102560A1 (en) * 2014-12-23 2016-06-30 The University Of Surrey Glycosylated biomarker
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
BR112017025255B1 (pt) * 2015-05-29 2024-02-27 Koninklijke Philips N.V Método implementado por computador, método e composição farmacêutica inibidora
US20190247461A1 (en) * 2015-09-23 2019-08-15 Centre National De La Recherche Scientifique Homeoproteins for use in the treatment of neurodegenerative disorders
CN106282347A (zh) * 2016-08-17 2017-01-04 中南大学 HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用
JP6855579B2 (ja) * 2016-12-28 2021-04-07 中国科学院広州生物医薬与健康研究院Ｇｕａｎｇｚｈｏｕ Ｉｎｓｔｉｔｕｔｅｓ Ｏｆ Ｂｉｏｍｅｄｉｃｉｎｅ Ａｎｄ Ｈｅａｌｔｈ，Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ Ｔ細胞を得る方法及び使用
KR101777085B1 (ko) 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
KR101777259B1 (ko) * 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
KR101777254B1 (ko) * 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
CN107894507A (zh) * 2017-11-22 2018-04-10 南宁科城汇信息科技有限公司 一种发现和鉴定肝癌血清差异表达蛋白和验证标志物蛋白方法
CN107727729A (zh) * 2017-11-22 2018-02-23 南宁科城汇信息科技有限公司 一种oa候选标志物诊断模型的建立方法
KR101923199B1 (ko) 2018-04-25 2018-11-28 주식회사 무진메디 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물
CN111363817B (zh) * 2018-12-26 2024-02-02 广州康立明生物科技股份有限公司 基于hoxd12基因的肺癌诊断剂及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510974A (ja) * 1997-06-27 2002-04-09 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒトｎｋ−３関連前立腺特異的遺伝子−１
RU2234942C2 (ru) * 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
WO2000023111A1 (en) * 1998-10-19 2000-04-27 Diadexus Llc Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU2001263771A1 (en) 2000-05-30 2001-12-11 Danmarks Miljo Undersogelser An assay method and kit for testing biological material for exposure to stress using biomarkers
WO2002002806A2 (en) * 2000-06-30 2002-01-10 Epigenomics Ag Method and nucleic acids for analysing the methylation of genes implicated in pharmacogenomics
AU2001292718A1 (en) * 2000-09-12 2002-03-26 Transgenetics Incorporated Microarrayed organization of transcription factor target genes
WO2002054936A2 (en) 2000-12-24 2002-07-18 Kohn, Kenneth, I. A method for detecting biomarkers
US20040063216A1 (en) 2000-12-24 2004-04-01 Iser Lubocki Method for detecting biomarkers
JP2004529630A (ja) * 2001-03-01 2004-09-30 エピゲノミクス アーゲー 診断および治療目的の遺伝子パネルを遺伝子の発現およびメチル化状態に基づいて開発する方法
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
CA2469089A1 (en) * 2003-07-08 2005-01-08 Institut De Recherches Cliniques De Montreal En-2 gene, disgnostic and therapeutic uses thereof
US20060014301A1 (en) 2004-07-13 2006-01-19 Power3 Medical Products, Inc. Antibody-based system for detection of differential protein expression patterns
WO2006071466A2 (en) * 2004-12-02 2006-07-06 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
US9416422B2 (en) * 2005-02-18 2016-08-16 Sloan-Kettering Institute For Cancer Research Methods for detecting minimum residual disease

Also Published As

Publication number Publication date
EP2115472A1 (en) 2009-11-11
CN101675341A (zh) 2010-03-17
US20100093558A1 (en) 2010-04-15
CA2671939A1 (en) 2008-06-26
BRPI0720371B1 (pt) 2019-05-28
RU2009127774A (ru) 2011-01-27
US8460882B2 (en) 2013-06-11
JP5683108B2 (ja) 2015-03-11
CY1115178T1 (el) 2016-12-14
ES2445185T3 (es) 2014-02-28
BRPI0720371B8 (pt) 2021-07-27
DK2115472T3 (da) 2014-02-10
SI2115472T1 (sl) 2014-05-30
RU2460075C2 (ru) 2012-08-27
GB0625321D0 (en) 2007-01-24
CN101675341B (zh) 2017-08-08
WO2008075056A1 (en) 2008-06-26
AU2007335999A1 (en) 2008-06-26
IL199241A (en) 2014-03-31
JP2010513901A (ja) 2010-04-30
EP2115472B1 (en) 2013-11-06
AU2007335999B2 (en) 2013-09-05
GB0719792D0 (en) 2007-11-21
NZ577548A (en) 2012-03-30
BRPI0720371A2 (pt) 2013-12-31
CA2671939C (en) 2017-10-03
MX2009006378A (es) 2009-08-24
PT2115472E (pt) 2014-02-14

Similar Documents

Publication Publication Date Title
GB0719792D0 (en) Cancer biomarkers
EP2009738A4 (en) ANTENNA
GB0612312D0 (en) Compact antenna
EP2095464A4 (en) COMPACT ANTENNA
GB0709295D0 (en) New Zealander
GB0905373D0 (en) Not published
IL186980A0 (en) Characterizing prostate cancer
DE602007006989D1 (en) Spiropiperidinderivate
TWI340501B (en) Noise-supressing antenna assamblage
GB0615902D0 (en) Antenna
GB0623160D0 (en) Biomolecules
GB0618127D0 (en) Biomarker
TWI329386B (en) Antenna
GB0618429D0 (en) Cancer test
GB0511302D0 (en) Biomarkers
EP2022500A4 (en) TUMOR SUPPRESSOR
GB0617605D0 (en) Biomarkers
GB2436166B (en) Liquid-coupled antenna
GB0720334D0 (en) Cancer biomarker
GB0607710D0 (en) Biomarkers
GB0610030D0 (en) Biomarkers
GB0620467D0 (en) Biomarker
GB0617223D0 (en) Complex
GB0624967D0 (en) Not published
GB0708064D0 (en) Biomarker